A catalyst for change: The european cancer patient's bill of rights

Oncologist

Volumn 19, Issue 3, 2014, Pages 217-224

  Lawler, Mark ^a   Le Chevalier, Thierry ^b   Murphy Jr , Martin J ^c   Banks, Ian ^d   Conte, Pierfranco ^e   De Lorenzo, Francesco ^f,g   Meunier, Françoise ^h   Pinedo, H M ⁱ   Selby, Peter ^j   Armand, Jean Pierre ^k   Barbacid, Mariano ^l   Barzach, Michèle ^m   Bergh, Jonas ⁿ   Bode, Gerlind ^o   Cameron, David A ^p   de Braud, Filippo ^q   de Gramont, Aimery ^r   Diehl, Volker ^s   Diler, Sarper ^t   Erdem, Sema ^u   Fitzpatrick, John M ^v,w   Geissler, Jan ^x,y   Hollywoodz, Donal ^z   Højgaard, Liselotte ^aa,ab   Horgan, Denis ^ac   Jassem, Jacek ^ad   Johnson, Peter W ^ae,af   Kapitein, Peter ^ag   Kellyv, Joan ^ah   Kloezen, Sandra ^ai   La Vecchia, Carlo ^aj   Löwenberg, Bob ^ak   Oliver, Kathy ^al   Sullivan, Richard ^am   Tabernero, Josep ^an   van de Velde, Cornelis J ^ao   Wilking, Nils ^n,ap   Wilson, Roger ^aq   Zielinski, Christoph ^ar   zur Hausen, Harald ^as   Johnston, Patrick G ^a   more..

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c European Cancer Concord Society for Translational Oncology   (United States)

^d European Men's Health Forum   (Belgium)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f Italian Federation of Volunteer based Cancer Organizations   (Italy)

^g European Cancer Patient Coalition   (Belgium)

^h EORTC DATA CENTER   (Belgium)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k INSTITUT CURIE   (France)

^l Centro Nacional de Investigaciones Oncológicas   (Spain)

^m IHU Strasbourg Board of Trustees   (France)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o International Confederation of Childhood Cancer Parent Organization (ICCCPO)   (Netherlands)

^p UNIVERSITY OF EDINBURGH   (United Kingdom)

^q NATIONAL CANCER INSTITUTE   (Italy)

^r HÔPITAL SAINT ANTOINE   (France)

^s UNIVERSITY OF COLOGNE   (Germany)

^t Myeloma Patients Europe   (Turkey)

^u EUROPA DONNA   (Italy)

^v Irish Cancer Society   (Ireland)

^w UNIVERSITY COLLEGE DUBLIN   (Ireland)

^x Leukemia Patient Advocates Foundation   (Switzerland)

^y European Patients Academy on Therapeutic Innovation   (Germany)

^z ST JAMES S HOSPITAL   (Ireland)

^aa DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^ab UNIVERSITY OF COPENHAGEN   (Denmark)

^ac European Alliance for Personalised Medicine   (Belgium)

^ad MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ae UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^af IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^ag Inspire2Live   (Netherlands)

^ah Association of European Cancer Leagues   (Belgium)

^ai Dutch Cancer Society   (Netherlands)

^aj MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^ak ERASMUS MEDICAL CENTER   (Netherlands)

^al International Brain Tumor Alliance   (United Kingdom)

^am KING'S COLLEGE LONDON   (United Kingdom)

^an VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^ao LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ap LUND UNIVERSITY HOSPITAL   (Sweden)

^aq Sarcoma Patients EuroNet   (Germany)

^ar MEDICAL UNIVERSITY OF VIENNA   (Austria)

^as UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIA; ARTICLE; AWARENESS; CANCER PATIENT; CANCER SCREENING; CLINICAL RESEARCH; CONTROL STRATEGY; COST CONTROL; EUROPE; EVIDENCE BASED PRACTICE CENTER; HEALTH CARE PERSONNEL; HUMAN; PALLIATIVE THERAPY; PATIENT CARE; PATIENT CARE PLANNING; PATIENT RIGHT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REHABILITATION PATIENT; EUROPEAN UNION; HEALTH CARE DISPARITY; LEGISLATION AND JURISPRUDENCE; NEOPLASMS;

EUROPE; EUROPEAN UNION; HEALTHCARE DISPARITIES; HUMANS; NEOPLASMS; PATIENT RIGHTS; PATIENT-CENTERED CARE;

EID: 84896463407     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0452     Document Type: Article

References (54)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Coleman MP, Quaresma M, Berrino F et al. Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756.
3. Giovino GA, Mirza SA, Samet JM et al. Tobacco use in 3 billion individuals from 16 countries: An analysis of nationally representative cross-sectional household surveys. Lancet 2012; 380: 668-679.
4. Soerjomataram I, Lortet-Tieulent J, Parkin DM et al. Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840-1850.
5. American Cancer Society. The global economic cost of cancer. Available at http://www. cancer. org/acs/groups/content/@internationalaffairs/documents/document/acspc-026203. pdf.
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
7. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
8. Rechel B, Grundy E, Robine JM et al. Ageing in the European Union. Lancet 2013; 381: 1312-1322.
9. World Health Organization Regional Office for Europe. European health report 2012: Charting the way to well-being. Available at http://www. euro. who. int/__data/assets/pdf_file/0003/184161/The-European-Health-Report-2012,-FULL-REPORTw-cover. pdf.
10. de Lorenzo F, Haylock P. Preface. Cancer 2013; 119(suppl 11): 2089-2093.
11. Johnston PG, Pinedo HM. The high tide of cancer research in Europe. The Oncologist 2011; 16: 539-542.
12. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24: 792-800.
13. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
14. Michels KB, zur Hausen H. HPV vaccine for all. Lancet 2009; 374: 268-270.
15. Khayat D. National Cancer Plans. Alexandria, VA: American Society of Clinical Oncology, 2013: 242-244.
16. National Cancer Research Institute. Welcome to the NCRI. Available at http://www. ncri. org. uk/.
17. Meunier F, Lawler M, Pinedo HM. Commentary: Fifty years of the European Organisation for Research and Treatment Of Cancer (EORTC)-making the difference for the European oncology community. The Oncologist 2012; 17: e6-e7.
18. Cardoso F, Piccart-Gebhart M, Van't Veer L et al. The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol 2007; 1: 246-251.
19. Wils J. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer 1998; 77(suppl 2): 23-28.
20. Mackenbach JP, Karanikolos M, McKee M. The unequal health of Europeans: Successes and failures of policies. Lancet 2013; 381: 1125-1134.
21. Autier P, Boniol M, La Vecchia C et al. Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis ofWHOmortality database. BMJ 2010; 341: c3620.
22. Sant M, Minicozzi P, Allemani C et al. Regional inequalities in cancer care persist in Italy and can influencesurvival. CancerEpidemiol2012; 36: 541-547.
23. Van der Heyden JH, SchaapMM, Kunst AE et al. Socioeconomic inequalities in lung cancer mortality in 16 European populations. Lung Cancer 2009; 63: 322-330.
24. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: A review. Ann Oncol 2006; 17: 5-19.
25. Quaglia A, Tavilla A, Shack L et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009; 45: 1006-1016.
26. DeAngelis R, SantM, ColemanMPet al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34.
27. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
28. European Commission. Impact assessment report on the revision of the "Clinical Trials Directive" 2001/20/EC. Available at http://ec. europa. eu/health/files/clinicaltrials/2012_07/impact_assessment_part1_en. pdf.
29. EuropeanCommission. Medicinal products for human use. Clinical trials: Revision of the clinical trials directive. Available at http://ec. europa. eu/health/human-use/clinical-trials/index_en. htm#rlctd.
30. EUnetHTA. Available at http://www. eunethta. eu/.
31. Purushotham A, Cornwell J, Burton C et al. What reallymatters in cancer?: Putting people back into the heart of cancer policy. Eur J Cancer 2013; 49: 1669-1672.
32. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065.
33. Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 2012; 30: 1715-1724.
34. Institute of Medicine. Delivering affordable cancer care in the 21st century-workshop summary. Available at http://www. iom. edu/Reports/2013/Delivering-Affordable-Cancer-Care-in-the-21st-Century. aspx.
35. U. S. Census Bureau Population Division. Interim projections consistent with census 2000 (released March 2004). Available at http://www. census. gov/population/www/projections/usinterimproj/. Accessed August 21, 2013.
36. National Research Council. Delivering highquality cancer care: Charting a new course for a system in crisis. Washington, DC: The National Academies Press, 2013:. Available at http://www. nap. edu/catalog. php?record_id518359. Accessed September 11, 2013.
37. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-980.
38. Wilking N, Jönsson B, Högberg D et al. Comparator report on patient access to cancer drugs in Europe. Available at http://www. comparatorreports. se/Comparator%20report%20on%20patient%20 access%20to%20cancer%20drugs%20in%20Europe %2015%20feb%2009. pdf.
39. Karanikolos M, Mladovsky P, Cylus J et al. Financial crisis, austerity, and health in Europe. Lancet 2013; 381: 1323-1331.
40. Luengo-Fernandez R, Leal J, Gray A et al. Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol 2013; 14: 1165-1174.
41. Wilking N, Jonsson B. Cancer and economics: With a special focus on cancer drugs. Oncol News 2011; 6: 17-19.
42. Khayat D. Innovative cancer therapies: Putting costs into context. Cancer 2012; 118: 2367-2371.
43. Wilking N, Kasteng F. A review of breast cancer care and outcomes in 18 countries in Europe, Asia and South America. Available at http://www. comparatorreports. se/A_review_of_breast_cancer_care_and_outcomes_26Oct2009. pdf.
44. Lichtenberg FR. Despite steep costs, payments for new cancer drugs make economic sense. Nat Med 2011; 17: 244.
45. Luce BR, Mauskopf J, Sloan FA et al. The return on investment in health care: From 1980 to 2000. Value Health 2006; 9: 146-156.
46. Soria JC, Blay JY, Spano JP et al. Added value of molecular targeted agents in oncology. Ann Oncol 2011; 22: 1703-1716.
47. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-486.
48. KantarjianHM, Fojo T, MathisenMet al. Cancer drugs in the United States: JustumPretium-the just price. J Clin Oncol 2013; 31: 3600-3604.
49. Pfister DG. The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution. J Clin Oncol 2013; 31: 3487-3489.
50. Kerr D. World summit against cancer for the new millennium: The Charter of Paris. Ann Oncol 2000; 11: 253-254.
51. Union for International Cancer Control. World Cancer Declaration. Available at http://www. uicc. org/world-cancer-declaration.
52. Slovensko predsedstvo EU 2008. Available at http://www. eu2008. si/en/News_and_Documents/Council_Conclusions/June/0609_EPSCO-cancer. pdf.
53. Association of European Cancer Leagues. What is the European code against cancer?. Available at http://www. cancercode. eu/.
54. Stop cancer now! Lancet 2013; 381: 426-427.